Mark D. Pegram, MD

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford's Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women's Cancer Center, discusses the development of trastuzumab biosimilars.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses challenges biosimilars will face once they hit the United States market.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses projections of cost reductions with biosimilars.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes the combination of pertuzumab and trastuzumab as a treatment for patients with HER2-positive metastatic breast cancer.

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.